Tristel (TSTL)

Sector:

Health Care

Index:

FTSE AIM 100

 370.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 500.00p
  • 52 Week Low: 270.00p
  • Currency: UK Pounds
  • Shares Issued: 47.71m
  • Volume: 8,634
  • Market Cap: £176.53m
  • RiskGrade: 180

Tristel OPH gets US FDA clearance

By Josh White

Date: Monday 12 May 2025

LONDON (ShareCast) - (Sharecast News) - Tristel announced on Monday that it has received FDA clearance to begin immediate sales of its ophthalmic disinfectant foam, Tristel OPH, in the United States.
The AIM-traded firm said the high-level disinfectant was approved for use on a range of reusable ophthalmic instruments, including tonometers, retinal imaging probes, and biometry devices that come into contact with the cornea.

It said the clearance was a significant opportunity in a market with around 16 million ophthalmic procedures annually across North America.

Tristel said its Tristel OPH product offered a faster and more practical alternative to the only previously FDA-cleared method, which involves chemical soaking in open trays with long contact times and occupational health concerns.

The new product, which has a two-minute contact time and was suitable for point-of-care use, was expected to replace both inefficient soak systems and low-level alternatives such as alcohol wipes.

Tristel said it had established US manufacturing through partner Parker Laboratories, adding that several leading eye institutes were preparing to adopt the product.

"We are delighted to receive FDA clearance for our second high level disinfectant product in the US," said chief executive officer Matt Sassone.

"Tristel OPH directly addresses a long-standing unmet need in ophthalmic device reprocessing-offering a fast, safe and practical alternative to the outdated and often hazardous methods still in use.

"Tristel OPH is the first FDA-cleared HLD specifically validated for use on ophthalmic devices meeting user requirements for efficacy, device compatibility and in-use safety."

Sassone said the company's commercial strategy built on the valuable learnings from launching Tristel ULT in the US.

"With an experienced local team and endorsement from ophthalmic device manufacturers we are well prepared to support early adopters and drive sustained growth in this important market.

"We are very excited to bring this new product to market in the US and perfectly timed to be showcased at the APIC - Association for Professionals in Infection Control and Epidemiology - conference in Phoenix, Arizona mid-June, the largest annual event in the US for reaching critical infection preventionist community and decision makers."

At 1122 BST, shares in Tristel were up 1.52% at 401p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Tristel Market Data

Currency UK Pounds
Share Price 370.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 500.00p
52 Week Low 270.00p
Volume 8,634
Shares Issued 47.71m
Market Cap £176.53m
RiskGrade 180

Tristel Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.89% below the market average94.89% below the market average94.89% below the market average94.89% below the market average94.89% below the market average
87.88% below the sector average87.88% below the sector average87.88% below the sector average87.88% below the sector average87.88% below the sector average
Price Trend
23.44% below the market average23.44% below the market average23.44% below the market average23.44% below the market average23.44% below the market average
2.7% below the sector average2.7% below the sector average2.7% below the sector average2.7% below the sector average2.7% below the sector average
Income
9.04% above the market average9.04% above the market average9.04% above the market average9.04% above the market average9.04% above the market average
75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average75.00% above the sector average
Growth
83.53% above the market average83.53% above the market average83.53% above the market average83.53% above the market average83.53% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 2
Buy 1
Neutral 1
Sell 0
Strong Sell 0
Total 4
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Tristel Dividends

  Latest Previous
  Interim Final
Ex-Div 20-Mar-25 28-Nov-24
Paid 11-Apr-25 20-Dec-24
Amount 5.68p 8.28p

Trades for 30-May-2025

Time Volume / Share Price
15:35 1,621 @ 369.70p
15:24 1,240 @ 361.00p
14:52 134 @ 369.70p
14:48 320 @ 361.40p
14:16 818 @ 369.70p

Tristel Key Personnel

Finance Director Elizabeth Dixon
CEO Matthew (Matt) Giovanni Sassone

Top of Page